HaploX Biotechnology

Founded in 2014, HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients. HaploX’s technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data. Presently, HaploX’s polycentric global distribution include: Shenzhen R & D Headquarter, Third-party Medical Laboratory, GMP Factory, US R & D center and ShangRao International Precision Medical Health Industrial Park. HaploX obtained a certificate of participation from EMQN(The European Molecular Genetics Quality Network) in 2017 and achieved both satisfactory results in two external quality assessment schemes: Lung Cancer(NSCLC)2 and Oncogene panel testing. HaploX possesses the most advanced platforms in the world: Illumina’s NextSeqs, HiSeq X Tens, NovaSeq 6000 series and digital PCR. HaploX’s throughput is now the second in the world rankings. In December 28th, 2017, HaploX Biotechnology raised $32 million in series A+ round. At the same time, NIVIDA accepted HaploX as a member in Inception program(a program started by NIVIDA in order to support startups that are revolutionizing industries with advances in artificial Intelligence and data science). The firm will continue to develop its sequencing technology, which is capable of detecting circulating tumor DNA for personalized cancer therapy.